Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; email:
Department of Chemical Engineering, University of Washington, Seattle, Washington, USA; email:
Annu Rev Chem Biomol Eng. 2022 Jun 10;13:325-346. doi: 10.1146/annurev-chembioeng-092220-030853. Epub 2022 Mar 23.
Brain disease remains a significant health, social, and economic burden with a high failure rate of translation of therapeutics to the clinic. Nanotherapeutics have represented a promising area of technology investment to improve drug bioavailability and delivery to the brain, with several successes for nanotherapeutic use for central nervous system disease that are currently in the clinic. However, renewed and continued research on the treatment of neurological disorders is critically needed. We explore the challenges of drug delivery to the brain and the ways in which nanotherapeutics can overcome these challenges. We provide a summary and overview of general design principles that can be applied to nanotherapeutics for uptake and penetration in the brain. We next highlight remaining questions that limit the translational potential of nanotherapeutics for application in the clinic. Lastly, we provide recommendations for ongoing preclinical research to improve the overall success of nanotherapeutics against neurological disease.
脑部疾病仍然是一个重大的健康、社会和经济负担,治疗方法向临床转化的成功率也很低。纳米疗法是提高药物生物利用度和向大脑输送药物的一种很有前途的技术投资领域,已有几种用于治疗中枢神经系统疾病的纳米疗法在临床上取得了成功。然而,目前迫切需要对治疗神经紊乱的方法进行新的和持续的研究。我们探讨了向大脑输送药物的挑战以及纳米疗法克服这些挑战的方法。我们提供了一个可以应用于脑内摄取和穿透的纳米疗法的一般设计原则的总结和概述。接下来,我们重点介绍了限制纳米疗法在临床上应用的转化潜力的一些尚存问题。最后,我们对正在进行的临床前研究提出了建议,以提高纳米疗法治疗神经疾病的整体成功率。